Aquestive Therapeutics (AQST) Cash Flow: Operating & Free Cash Flow

Aquestive Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Aquestive Therapeutics, Inc. (AQST) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	-83.78	-44.14	-7.87	-54.41	-70.54	-55.78	-66.25	-61.38	-8.94
Depreciation & Amortization	0.55	0.72	1.35	2.39	2.96	3.61	2.91	3.24	3.80
Deferred Income Tax	0.00	0.00	0.00	0.00	0.00	0.00	4.90	5.28	0.00
Stock Based Compensation	7.62	7.10	2.69	4.38	6.82	6.58	7.07	29.94	0.00
Change in Working Capital	12.18	-9.96	-5.34	32.01	-1.73	-4.41	-11.12	8.00	7.88
Change in Accounts Receivable	-10.37	1.09	-3.07	7.35	-5.35	6.18	-7.44	-0.41	4.69
Change in Inventory	-0.13	0.73	-0.99	-1.74	-1.58	0.40	2.58	-1.43	-1.13
Change in Accounts Payable	19.52	2.78	-1.02	1.63	1.23	-2.21	-7.87	11.32	2.94
Change in Other Working Capital	11.00	-14.56	1.77	24.77	1.26	-7.95	1.60	-1.49	1.38
Other Operating Activities	11.00	10.52	1.77	5.85	29.51	1.96	2.29	1.93	3.09
Net Cash from Operating Activities	-52.43	-35.76	-6.38	-9.79	-32.98	-45.46	-60.21	-12.99	5.82
Investing Activities
Capital Expenditures	-0.56	-0.16	-1.00	-2.52	-0.91	-0.52	-0.66	-1.82	-2.07
Net Cash from Investing Activities	-0.56	-0.16	-1.00	-2.52	-0.91	-0.52	-0.66	-1.82	-2.07
Financing Activities
Debt Repayment	-0.03	-0.02	-53.63	-2.03	0.00	-22.50	17.06	0.00	5.00
Common Stock Issued	100.65	83.76	8.91	13.59	30.12	6.69	39.32	68.83	0.02
Common Stock Repurchased	0.00	0.00	-0.01	0.00	-0.01	-0.10	0.00	0.00	0.00
Other Financing Activities	-0.82	-0.14	9.20	0.00	-0.01	44.37	-6.77	-10.80	-0.59
Net Cash from Financing Activities	102.62	83.59	3.97	11.56	30.11	28.46	49.60	58.04	4.41
Summary
Net Change in Cash	49.62	47.67	-3.40	-0.75	-3.78	-17.52	-11.27	43.22	8.17
Cash at Beginning of Period	71.55	23.87	27.27	28.02	31.81	49.33	60.60	17.38	9.21
Cash at End of Period	121.17	71.55	23.87	27.27	28.02	31.81	49.33	60.60	17.38
Free Cash Flow	-52.99	-35.92	-7.38	-12.31	-33.89	-45.98	-60.87	-14.82	3.76
Supplemental Disclosures
Interest Paid	-	7.10	4.60	6.44	6.44	8.49	-	-	-
Income Taxes Paid	-	0.31	-	-	-	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Aquestive Therapeutics Cash Flow

What is Aquestive Therapeutics's free cash flow?

Aquestive Therapeutics had negative free cash flow of $52.99M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$52.43M minus $562.00K of capital expenditures.

How much does Aquestive Therapeutics spend on capital expenditures?

Aquestive Therapeutics spent $562.00K on capital expenditures in fiscal 2025, compared with $159.00K a year earlier.

Does Aquestive Therapeutics pay dividends or buy back shares?

Aquestive Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition